首页|期刊导航|临床眼科杂志|雷珠单抗联合前列地尔对早期糖尿病视网膜病变的疗效及视觉电生理的影响

雷珠单抗联合前列地尔对早期糖尿病视网膜病变的疗效及视觉电生理的影响OA

Effects of lucentis combined with alprostadil on early diabetic retinopathy and visual electrophysiology

中文摘要英文摘要

目的 探究雷珠单抗联合前列地尔对早期糖尿病视网膜病变(DR)的疗效及视觉电生理的影响.方法 选取2022年10月至2024年10月我院收治的94例DR患者进行前瞻性随机对照研究,采用随机数字表法分为观察组(n=47)和对照组(n=47).对照组进行雷珠单抗注射治疗,观察组采用雷珠单抗联合前列地尔治疗.评估两组临床疗效,检测患者临床指标[眼压、视力及黄斑中心凹厚度(CMT)],比较两组视觉电生理指标及血管内皮指标,并进行安全性评价.结果 观察组治疗总有效率(93.62%)高于对照组(78.72%)(P<0.05);2组治疗后眼压、CMT下降,视力升高(均P<0.05),观察组治疗后眼压、CMT较对照组下降,视力较对照组升高(均P<0.05);2组治疗后P50、N95潜伏期缩短,P50、N95波振幅上升(均P<0.05),观察组治疗后P50、N95潜伏期较对照组缩短,P50、N95波振幅较对照组上升(均P<0.05);2组治疗后血管内皮生长因子(VEGF)、内皮素-1(ET-1)水平降低,一氧化氮(NO)水平升高(均P<0.05),观察组VEGF、ET-1水平较对照组降低,NO水平对照组升高(均P<0.05);观察组、对照组不良反应发生率比较(17.02%vs.10.64%),差异无统计学意义(P>0.05).结论 雷珠单抗联合前列地尔能够提高早期DR患者的临床疗效,改善视觉电生理指标并降低血管内皮损伤,安全有效.

Objective To investigate the effect of lucentis combined with alprostadil on early diabetic retinopa-thy(DR)and the effects of visual electrophysiology.Methods A prospective randomized controlled study was conducted on 94 DR patients who were admitted to our hospital from October 2022 to October 2024.They were divided into the obser-vation group(n=47)and the control group(n=47)by random number table method.The control group was treated with lei-zumab injection,and the observation group was treated with leizumab combined with alprostadil.The clinical efficacy of the two groups was evaluated,and the clinical indicators included intraocular pressure(IOP),visual acuity and central macular thiekness(CMT)were measured.The visual electrophysiological indexes and vascular endothelial indexes were compared between the two groups,and the safety was evaluated.Results The total effective rate of the observation group(93.62%)was higher than that of the control group(78.72%)(P<0.05).After the treatment,IOP and CMT decreased and visual acuity increased in both groups(all P<0.05).After the treatment,the IOP and CMT of the observation group decreased and the vi-sual acuity was increased in the control group(all P<0.05).After the treatment,the latency of P50 and N95 was shortened and the amplitudes of P50 and N95 waves were increased in both groups(all P<0.05).Compared with the control group,the observation group had shorter P50 and N95 latency and higher P50 and N95 amplitudes after treatment(all P<0.05).The vascular endothelial growth factor(VEGF)and endothelin-1(ET-1)levels were decreased and NO level were increased in both groups after the treatment(all P<0.05).The levels of VEGF and ET-1 in the observation group were lower than those in the control group,while the levels of NO in the control group were increased(all P<0.05).There was no significant differ-ence in the in cidence of adverse reactions between the observation group and the control group(17.02%vs.10.64%)(P>0.05).Conclusions Lucentis combined with alprostadil can improve the clinical efficacy of early DR patients,improve vi-sual electrophysiological indexes and reduce vascular endothelial injury,and is safe and effective.

雍焱隽;李辰;董彦平;苏楠;刘辉;王俊成

730050 甘肃兰州,兰州市第一人民医院眼科730050 甘肃兰州,兰州市第一人民医院眼科730050 甘肃兰州,兰州市第一人民医院眼科730050 甘肃兰州,兰州市第一人民医院眼科730050 甘肃兰州,兰州市第一人民医院眼科730999 甘肃白银,白银市第一人民医院眼科

糖尿病视网膜病变雷珠单抗前列地尔视觉电生理疗效

Diabetic retinopathyLucentisAlprostadilVisual electrophysiologyCurative effect

《临床眼科杂志》 2026 (4)

309-313,5

甘肃省科技项目(LH20201016)

10.3969/j.issn.1006-8422.2026.04.004

评论